We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral IPN60130 for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP). (FALKON)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05039515
Recruitment Status : Recruiting
First Posted : September 9, 2021
Last Update Posted : November 22, 2022
Sponsor:
Collaborator:
Ipsen
Information provided by (Responsible Party):
Ipsen ( Clementia Pharmaceuticals Inc. )

Brief Summary:

Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by the presence of bone in soft tissue where bone normally does not exist, known as Heterotopic Ossification (HO). It is often associated with painful, recurrent episodes of soft tissue swelling (flare-ups) that lead to abnormal stiffening and immobility (ankyloses) of major joints with cumulative and irreversible loss of movement and disability.

This study will evaluate the efficacy of 2 dosing regimens of IPN60130 in inhibiting new HO volume compared with placebo (a dummy treatment) in adult and paediatric participants with FOP. It will be assessed by a scan (provides internal images of the body) called low dose Whole Body Computed Tomography (WBCT), excluding head.

Adults and participants 15 years of age or older are also eligible for a sub study to evaluate HO lesions assessed by another type of scan, Fluorine-18-labelled natrium fluoride Positron Emission Tomography-Computed Tomography ([18F]NaF PET-CT ).


Condition or disease Intervention/treatment Phase
Fibrodysplasia Ossificans Progressiva Drug: IPN60130 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Two-part, Placebo-controlled, Parallel-group, Double-blind Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral IPN60130 for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Participants 5 Years of Age and Older.
Actual Study Start Date : December 1, 2021
Estimated Primary Completion Date : August 30, 2025
Estimated Study Completion Date : August 30, 2025


Arm Intervention/treatment
Experimental: IPN60130 high dosage
Oral capsule, swallowed whole or sprinkled onto food, once daily
Drug: IPN60130
Immediate-release capsule containing high dose of the drug substance.

Experimental: IPN60130 low dosage
Oral capsule, swallowed whole or sprinkled onto food, once daily
Drug: IPN60130
Immediate-release capsule containing low dose of the drug substance.

Placebo Comparator: Placebo
Oral capsule, swallowed whole or sprinkled onto food, once daily
Drug: Placebo
Placebo will be supplied as powder filled hard capsules




Primary Outcome Measures :
  1. Annualized change in HO volume as assessed by low-dose WBCT (excluding the head) in treated participants receiving IPN60130 compared with placebo. [ Time Frame: From baseline to 12 months ]
  2. Incidence of Adverse Events / Serious Adverse Events (AEs/SAE) [ Time Frame: From baseline until the end of study (25 months) ]

Secondary Outcome Measures :
  1. Change in HO volume of new HO lesions as detected by WBCT in participants receiving IPN60130 compared with placebo recipients [ Time Frame: from baseline up to 12 months ]
  2. Change in number of HO lesions by WBCT in participants receiving IPN60130 compared with placebo recipients [ Time Frame: from baseline up to 12 months ]
  3. Flare-up rate and number of flare-up days in participants receiving IPN60130 compared with placebo recipients [ Time Frame: from baseline up to 12 months ]
  4. The number of body regions with new HO in participants receiving IPN60130 compared with placebo recipients [ Time Frame: from baseline up to 12 months ]
  5. Change in pain intensity over time using the Numeric pain rating scale (NRS) in participants ≥13 years old and Wong Baker Faces Pain Scale (FPS) in participants <13 years old in participants receiving IPN60130 compared with placebo recipients [ Time Frame: from baseline up to 12 months ]
  6. The proportion of participants with any new HO in participants receiving IPN60130 compared with placebo recipients [ Time Frame: from baseline up to 12 months ]
  7. Change from baseline in HO volume as detected by WBCT in participants receiving IPN60130 compared with placebo recipients and with participants receiving the standard of care in the Natural history study (NHS) [ Time Frame: from baseline up to 24 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   5 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Written, signed, and dated informed subject/parent consent; and for subjects who are minors, age-appropriate assent (performed according to local regulations).
  • Participants must be clinically diagnosed with FOP, with the R206H ACVR1 mutation or other FOP variants associated with progressive HO.
  • Participants must have disease progression in the preceding year of the screening visit.
  • Participants who have participated in a prior clinical study using another investigational product for the treatment of FOP may be enrolled after a washout of at least 5 half-lives of the other investigational product. Participants with prior treatment such as, but not limited to, imatinib, isotretinoin, garetosmab or palovarotene may be enrolled 30 days after discontinuation or after washout of at least 5 half-lives, whichever is longer.
  • Participants must be able to perform pulmonary function tests adequately and reliably.
  • Participants must be able to have an adequate echocardiography assessment at screening for evaluation of left ventricular structure and function as defined by the protocol.
  • Participants must be accessible for treatment and follow-up and be able to undergo all study procedures. Participants living at distant locations from the investigational site must be able and willing to travel to a site for the initial and all on-site follow-up visits. Participants must be able to undergo low-dose WBCT (excluding head) without sedation.
  • Body weight ≥10 kg.
  • Abstinent or using two highly effective forms of birth control. Females must also have a negative blood or urine pregnancy test prior to administration of study drug.

Key Exclusion Criteria:

  • Participants with complete heart block and left bundle branch block on screening electrocardiogram.
  • Participants with screening echocardiography showing septal or left ventricular free wall thickness >12 mm for adult participants or a z-score >3 compared with population norms for children and adolescent participants or left ventricular ejection fraction (LVEF) <50%.
  • Participants with severe mitral or tricuspid regurgitation on echocardiography at screening.
  • Participants with significant underlying lung disease requiring supplementary oxygen or forced vital capacity <35% of predicted at screening.
  • Participants with uncontrolled cardiovascular, hepatic, pulmonary, gastrointestinal, endocrine, metabolic, ophthalmologic, immunologic, psychiatric, or another significant disease as judged by the investigator.
  • Participants with severe hepatic impairment.
  • Concomitant medications that are strong inhibitors (including grapefruit juice) or inducers (including St John's Wort) of cytochrome P450 (CYP) 3A4 activity; or kinase inhibitors such as imatinib.
  • Prior use in the past year and concomitant use of bisphosphonates for participants in the PET-CT sub study.
  • Concurrent participation in another interventional clinical study, or a noninterventional study with radiographic measures or invasive procedures (e.g. collection of blood or tissue samples).
  • Amylase or lipase >2× the upper limit of normal (ULN) or with a history of chronic pancreatitis.
  • Elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >5×ULN.
  • Participants with hematologic abnormalities:

    • Hgb<10g/dL
    • Platelets<75,000/mm3
    • WBC<2000/mm3
    • Participants with coagulation test measurements outside of the normal range at screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05039515


Contacts
Layout table for location contacts
Contact: Ipsen Recruitment Enquiries see email clinical.trials@ipsen.com

Locations
Show Show 24 study locations
Sponsors and Collaborators
Clementia Pharmaceuticals Inc.
Ipsen
Investigators
Layout table for investigator information
Study Director: Ipsen Medical Director Ipsen
Layout table for additonal information
Responsible Party: Clementia Pharmaceuticals Inc.
ClinicalTrials.gov Identifier: NCT05039515    
Other Study ID Numbers: D-CA-60130-452
2020-002858-24 ( EudraCT Number )
First Posted: September 9, 2021    Key Record Dates
Last Update Posted: November 22, 2022
Last Verified: November 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Where patient data can be anonymised, Ipsen will share all individual participant data that underlie the results reported in the published journal article with qualified researchers who provide a valid research question. Study documents, such as the study protocol and clinical study report, are not always available.
Time Frame: Data are available beginning 6 months and ending 5 years after the publication of the findings in a journal; after this time, only raw data may be available.
Access Criteria: Proposals should be submitted to DataSharing@ipsen.com and will be assessed by a scientific review board.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Myositis Ossificans
Myositis
Muscular Diseases
Musculoskeletal Diseases